evaluating RDEA#

Related by string. * EVALUATING . EVALUATED . Evaluated . evaluated . Evaluating : evaluating CK # . When evaluating Antigenics . rigorously evaluated . Intervention Trial Evaluating . evaluating OGX . prospectively evaluated . evaluating Nexavar . evaluating ispinesib . evaluating pirfenidone / : MEK inhibitor RDEA# . RDEA# RDEA# RDEA# RDEA# . mg RDEA# . HIV RDEA# . RDEA# potent . RDEA# * *

Related by context. Frequent words. (Click for all words.) 62 Phase 1b 62 Phase 2a 61 Phase 2b study 60 Phase 2a trial 60 Phase 2a clinical 59 Phase 2b clinical 59 phase IIb 59 Phase 2b trial 58 multiple ascending dose 58 Phase IIb clinical 57 Phase Ib 57 Phase IIb 57 Phase IIa trial 56 NGX# 56 PRX # 55 initiate Phase 55 Phase IIb trial 55 pivotal Phase III 55 confirmatory Phase 3 55 HGS ETR1 54 Phase 2b 54 CRx 54 Phase III 54 Phase IIa 54 Phase II 54 Phase IIa clinical 53 Phase III pivotal 53 Phase III clinical 53 IDX# 52 CORLUX 52 pivotal Phase 52 RDEA# 52 ofatumumab 52 dose escalation trial 52 NUVIGIL 51 CoFactor 51 mipomersen 51 single ascending dose 51 ISIS # 50 Androxal 50 belinostat 50 DSMB 50 MGCD# [001] 50 perifosine 50 ZYBRESTAT 50 denufosol 50 Ventavis 49 avanafil 49 cetrorelix 49 INCB# [002] 49 RG# [001] 49 IMGN# 49 Phase 49 Initiates Phase 49 monotherapy 48 randomized Phase 48 blind randomized placebo 48 randomized controlled clinical 48 HspE7 48 Perifosine 48 laquinimod 48 Marqibo 48 MDV# 48 IND enabling 48 Azixa 48 randomized controlled 48 ThermoDox 48 investigational compound 47 XL# [003] 47 tamibarotene 47 CA4P 47 LibiGel 47 oral formulation 47 dose escalation 47 ADX# 47 Zerenex 47 picoplatin 47 talactoferrin 46 GRN#L 46 dose escalation study 46 LEVADEX 46 blinatumomab 46 microplasmin 46 unblinded 46 Investigational Device Exemption IDE 46 L MTP PE 46 NDA submission 46 relapsing remitting multiple sclerosis 46 PF # [001] 46 daclizumab 46 investigational oral 46 AZD# 46 AP# [003] 46 multicenter randomized double 46 CYT# 46 placebo controlled 45 Zenvia 45 FOLOTYN 45 Bronchitol 45 intravenous formulation 45 pralatrexate

Back to home page